As of Friday close, ResMed Inc.’s (NYSE:RMD) stock was down -$40.7, moving down -18.50 percent to $179.25. The average number of shares traded per day over the past five days has been 1,175,140 shares. 2 times new highs have been achieved over the past 5 days, with a -$43.92 fall in that time frame. In the last twenty days, the average volume was 719,695, while in the previous 50 days, it was 737,052.
Since last month, RMD stock retreated -16.63%. Shares of the company fell to $178.16 on 08/04/23, the lowest level in the past month. A 52-week high of $247.65 was reached on 04/28/23 after having rallying from a 52-week low of $202.04. Since the beginning of this year, RMD’s stock price has dropped by -13.88% or -$28.88, and marked a new high 9 times. However, the stock has declined by -27.62% since its 52-week high.
RMD stock investors should be aware that ResMed Inc. (RMD) stock had its last reported insider trading activity 4 days ago on Aug 01. Rider Michael J, the Global General Counsel of the company, disposed of 25 shares for $224.12 on Aug 01. It resulted in a $5,603 divestment by the insider. Farrell Michael J. sold 5,675 shares at an average price of $221.27 on Jul 17. The insider now owns 436,930 shares following the transaction. On Jul 17, President and COO Douglas Robert Andrew sold 1,500 shares at $222.22 apiece. The transaction was valued at $333,330.
Valuation Metrics
Right now, ResMed Inc. (RMD) has a P/E ratio of about 30.59. The stock’s beta is 0.48. Besides these, the trailing price-to-sales (P/S) ratio of 6.51, the price-to-book (PB) ratio of 6.70, and the price-to-cash flow ratio of 171.41 may also be considered.
The latest dividend of $0.48 per share was paid out, which is 9.09% more than last year’s $0.44.
Financial Health
In the three months ended March 30, ResMed Inc.’s quick ratio stood at 1.70, while its current ratio was 3.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.40, and the total debt-to-equity ratio was 0.40. On the profitability front, the trailing twelve-month gross margin is 56.30% percent. In the year ended March 30, EBITDA margin amounted to 33.37%, whereas operating margins totaled 27.70%. Based on annual data, RMD earned $2.02 billion in gross profit and brought in $3.58 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 19.80%. Return on equity (ROE) for the past 12 months was 23.90%.
In ResMed Inc.’s quarter-end financial report for March 30, it reported total debt of $1.58 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RMD’s revenue fell -10.67% to $1.03 billion during the quarter, while net income inched up to $1.11 billion. While analysts expected ResMed Inc. to report $1.59 quarterly earnings, the actual figure was $1.68 per share, beating the consensus estimate by 5.70%. During the quarter, the company generated $353.46 million in EBITDA. The liabilities of ResMed Inc. were 2.78 billion at the end of its most recent quarter ended March 30, and its total debt was $1.58 billion. The value of shareholders’ equity is $146.93 million.
Technical Picture
This quick technical analysis looks at ResMed Inc.’s (RMD) price momentum. With a historical volatility rate of 101.95%, the RSI 9-day stood at 12.29% on 04 August.
With respect to its five-day moving average, the current ResMed Inc. price is down by -19.68% percent or -$43.92. At present, RMD shares trade -16.94% below its 20-day simple moving average and -13.12% percent below its 100-day simple moving average. However, the stock is currently trading approximately -19.46% below its SMA50 and -16.63% below its SMA200.
Stochastic coefficient K was 20.34% and Stochastic coefficient D was 37.79%, while ATR was 8.11. Given the Stochastic reading of 2.10% for the 14-day period, the RSI (14) reading has been calculated as 17.59%. As of today, the MACD Oscillator reading stands at -10.14, while the 14-day reading stands at -10.88.
Analyst Ratings
RBC Capital Mkts upgraded its rating on ResMed Inc. (NYSE: RMD) to an Outperform in a note to investors on August 01, 2023. The analysts firm previously had a Sector perform rating on the stock.ResMed Inc. (RMD) has been rated Overweight by analysts. According to 0 brokerage firms, RMD is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 5 analysts rate ResMed Inc. stock as buy, with 14 recommending it as overweight.
With a median target price of $242.44, the current consensus forecast for the stock is $206.78 – $284.00. Based on these forecasts, analysts predict ResMed Inc. (RMD) will achieve an average price target of $244.53.
